Company research
Cryoport, Inc.
CIK 1124524Updated Sep 24, 2026
SecurityCYRX · NASDAQ · equity
Name history
CRYOPORT SYSTEMS INC · through Oct 20, 2005
CYRX price & chart
Loading TradingView…
NASDAQ:CYRX on TradingView ↗About the company
Cryoport, Inc. (Nasdaq: CYRX) is a leading global provider of integrated temperature-controlled supply chain solutions for the life sciences, with an emphasis on regenerative medicine. We support biopharmaceutical companies, contract manufacturers (CDMOs), contract research organizations (CROs), developers, and researchers with a comprehensive suite of services and products designed to minimize risk and maximize reliability across the temperature-controlled supply chain for the life sciences. Our integrated supply chain platform includes the Cryoportal® Logistics Management Platform, advanced temperature-controlled packaging, informatics, specialized BioLogistics, BioStorage, BioServices, cryopreservation services, and cryogenic systems, which in varying combinations deliver end-to-end solutions that meet the rigorous demands of the life sciences. With innovation, regulatory compliance, and agility at our core, we are "Enabling the Future of Medicine™."
In the news
Cryoport to Report Third Quarter 2025 Financial Results on November 4, 2025 News provided by Cryoport, Inc. Oct 21, 2025, 08:00 ET Share this article Share to X Share this article Share to X NASHVILLE, Tenn. , Oct. 21, 2025 /PRNewswire/ -- Cryoport, Inc. (Nasdaq: CYRX ) ("Cryoport" or the "Company") ↗
Recent filings
SCHEDULE 13G/A filing
144 filing
10-Q filing
Results of Operations and Financial Condition
Items 2.02, 9.01
SCHEDULE 13G/A filing
Show 5 more recent filings
Financials
FY 2025 · USDSource
Source
Source
Source
Source
Source
balance sheet · annual statements
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|
| ASSETS | ||||
| AssetsUSD | 764,989,000Source | 703,492,000Source | 957,744,000Source | 1,038,746,000Source |
| Property, Plant and Equipment, NetUSD | 85,448,000Source | 88,839,000Source | 84,858,000Source | 63,603,000Source |
| GoodwillUSD | 22,400,000Source | 51,660,000Source | 108,403,000Source | 151,117,000Source |
| Current assets: | ||||
| Cash and Cash Equivalents, at Carrying ValueUSD | 250,494,000Source | 45,289,000Source | 46,346,000Source | 36,595,000Source |
| Accounts Receivable, after Allowance for Credit Loss, CurrentUSD | 33,359,000Source | 45,778,000Source | 42,074,000Source | 43,858,000Source |
| Inventory, NetUSD | 23,188,000Source | 22,470,000Source | 26,206,000Source | 27,678,000Source |
| Assets, CurrentUSD | 476,174,000Source | 341,571,000Source | 535,112,000Source | 604,176,000Source |
| Prepaid Expense and Other Assets, CurrentUSD | 8,419,000Source | 11,574,000Source | 10,077,000Source | 9,317,000Source |
| Operating Lease, Right-of-Use AssetUSD | 39,720,000Source | 47,188,000Source | 32,653,000Source | 26,877,000Source |
| Other Assets, NoncurrentUSD | — | — | — | 947,000Source |
| LIABILITIES AND EQUITY | ||||
| LiabilitiesUSD | 262,351,000Source | 301,594,000Source | 468,721,000Source | 482,908,000Source |
| Stockholders’ equity: | ||||
| Common Stock, Value, IssuedUSD | 50,000Source | 50,000Source | 49,000Source | 48,000Source |
| Additional Paid in CapitalUSD | 1,152,680,000Source | 1,145,677,000Source | 1,131,183,000Source | — |
| Retained Earnings (Accumulated Deficit)USD | -688,884,000Source | -757,175,000Source | -642,419,000Source | -542,832,000Source |
| Accumulated Other Comprehensive Income (Loss), Net of TaxUSD | -3,483,000Source | -20,929,000Source | -26,065,000Source | — |
| Stockholders' Equity Attributable to ParentUSD | 502,638,000Source | 401,898,000Source | 489,023,000Source | 555,838,000Source |
| Additional Paid in Capital, Common StockUSD | — | — | — | 1,114,896,000Source |
| Liabilities and EquityUSD | 764,989,000Source | 703,492,000Source | 957,744,000Source | 1,038,746,000Source |
| Current liabilities: | ||||
| Liabilities, CurrentUSD | 219,018,000Source | 64,563,000Source | 45,610,000Source | 40,851,000Source |
| Operating Lease, Liability, CurrentUSD | 4,133,000Source | 5,419,000Source | 5,371,000Source | 3,720,000Source |
| Operating Lease, Liability, NoncurrentUSD | 39,078,000Source | 44,077,000Source | 29,355,000Source | 24,721,000Source |
| Deferred Income Tax Liabilities, NetUSD | 1,354,000Source | 2,531,000Source | 2,816,000Source | 4,929,000Source |
| Other Liabilities, NoncurrentUSD | 444,000Source | 394,000Source | 601,000Source | 451,000Source |
| Additional Financial Items | ||||
| Cash, Cash Equivalents, and Short-term InvestmentsUSD | 411,208,000Source | 261,749,000Source | 456,755,000Source | 523,323,000Source |
| Deferred Tax Liabilities, NetUSD | 281,000Source | 1,663,000Source | 2,160,000Source | 3,982,000Source |
| Short-term InvestmentsUSD | 160,714,000Source | 216,460,000Source | 410,409,000Source | 486,728,000Source |
cash flow · annual statements
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|
| Cash flows from operating activities: | ||||
| Net Income (Loss), Including Portion Attributable to Noncontrolling InterestUSD | 78,301,000Source | -114,756,000Source | — | -37,333,000Source |
| Adjustments to reconcile net income to net cash provided by operating activities: | ||||
| Depreciation, Depletion and AmortizationUSD | 27,712,000Source | 30,757,000Source | 27,487,000Source | 22,765,000Source |
| Share-based Payment Arrangement, Noncash ExpenseUSD | 10,066,000Source | 19,704,000Source | 22,808,000Source | 20,082,000Source |
| Changes in operating assets and liabilities: | ||||
| Increase (Decrease) in InventoriesUSD | 2,185,000Source | -3,252,000Source | -1,508,000Source | 14,204,000Source |
| Deferred Income Tax Expense (Benefit)USD | 661,000Source | -377,000Source | — | -411,000Source |
| Net Cash Provided by (Used in) Operating ActivitiesUSD | -8,580,000Source | -16,323,000Source | -757,000Source | -1,851,000Source |
| Cash flows from investing activities: | ||||
| Payments to Acquire Businesses, Net of Cash AcquiredUSD | — | 313,000Source | 7,341,000Source | 6,554,000Source |
| Net Cash Provided by (Used in) Investing ActivitiesUSD | 250,323,000Source | 176,815,000Source | 36,045,000Source | -59,681,000Source |
| Payments to Acquire Property, Plant, and EquipmentUSD | 16,439,000Source | 17,254,000Source | 38,785,000Source | 22,107,000Source |
| Cash flows from financing activities: | ||||
| Payments for Repurchase of Common StockUSD | 10,011,000Source | — | — | 37,960,000Source |
| Net Cash Provided by (Used in) Financing ActivitiesUSD | -21,074,000Source | -161,531,000Source | -23,798,000Source | -39,174,000Source |
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate EffectUSD | 205,205,000Source | -1,057,000Source | 9,751,000Source | -102,506,000Source |
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash EquivalentsUSD | 250,494,000Source | 45,289,000Source | 46,346,000Source | 36,595,000Source |
| Supplemental disclosure of cash flow information: | ||||
| Interest Paid, Excluding Capitalized Interest, Operating ActivitiesUSD | 1,628,000Source | 2,693,000Source | 3,399,000Source | 3,628,000Source |
| Income Taxes Paid, NetUSD | 1,939,000Source | — | — | — |
| Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash and Restricted Cash EquivalentsUSD | -15,464,000Source | -18,000Source | -1,739,000Source | -1,800,000Source |
| Additional Financial Items | ||||
| Share-based Payment Arrangement, ExpenseUSD | 11,032,000Source | 19,704,000Source | 22,808,000Source | 20,082,000Source |
| Amortization of Debt Issuance CostsUSD | — | — | 2,526,000Source | 2,537,000Source |
| Amortization of Debt Issuance Costs and DiscountsUSD | 1,221,000Source | 1,940,000Source | 2,526,000Source | 2,581,000Source |
| Amortization of Intangible AssetsUSD | 12,700,000Source | 17,000,000Source | 16,300,000Source | 15,100,000Source |
| Cash, Cash Equivalents, and Short-term InvestmentsUSD | 411,208,000Source | 261,749,000Source | 456,755,000Source | 523,323,000Source |
| Debt Securities, Available-for-sale, Realized Gain (Loss)USD | -2,209,000Source | -4,100,000Source | -67,000Source | -100,000Source |
| Deferred Other Tax Expense (Benefit)USD | — | — | — | 8,983,000Source |
| DepreciationUSD | 12,500,000Source | 13,600,000Source | 11,200,000Source | 7,700,000Source |
| Disposal Group, Not Discontinued Operation, Gain (Loss) on DisposalUSD | -1,012,000Source | -384,000Source | -954,000Source | -800,000Source |
| Equity Securities, FV-NI, Realized Gain (Loss)USD | -203,000Source | -3,370,000Source | -3,764,000Source | -11,406,000Source |
| Equity Securities, FV-NI, Unrealized Gain (Loss)USD | 1,506,000Source | -899,000Source | 1,308,000Source | -11,406,000Source |
| Foreign Currency Transaction Gain (Loss), before TaxUSD | 12,900,000Source | -4,300,000Source | -1,300,000Source | -9,800,000Source |
| Gain (Loss) on Disposition of BusinessUSD | 116,953,000Source | — | — | — |
| Gain (Loss) on Extinguishment of DebtUSD | — | 18,505,000Source | 5,679,000Source | — |
| GoodwillUSD | 22,400,000Source | 51,660,000Source | 108,403,000Source | 151,117,000Source |
| Goodwill, Impairment LossUSD | 0Source | 54,563,000Source | 49,569,000Source | — |
| Impairment of Intangible Assets, Finite-livedUSD | 0Source | — | — | — |
| Impairment of Intangible Assets, Indefinite-lived (Excluding Goodwill)USD | 0Source | — | — | — |
| Income (Loss) from Continuing Operations, Net of Tax, Attributable to ParentUSD | -33,969,000Source | — | — | — |
| Income (Loss) from Discontinued Operations, Net of Tax, Attributable to ParentUSD | 112,270,000Source | — | — | — |
| Income Tax Expense (Benefit)USD | 1,799,000Source | 1,276,000Source | 239,000Source | 2,239,000Source |
| InterestExpenseNonoperatingUSD | 2,361,000Source | 4,108,000Source | — | — |
| Net Income (Loss) Attributable to ParentUSD | 78,301,000Source | -114,756,000Source | -99,587,000Source | -37,333,000Source |
| Net Income (Loss) Available to Common Stockholders, BasicUSD | 70,301,000Source | -122,756,000Source | -107,587,000Source | -45,333,000Source |
| Nonoperating Income (Expense)USD | 4,636,000Source | 17,386,000Source | 15,809,000Source | -3,190,000Source |
| Operating ExpensesUSD | 119,860,000Source | 230,497,000Source | 214,489,000Source | 135,777,000Source |
| Operating Lease, ExpenseUSD | 6,596,000Source | 5,770,000Source | 5,103,000Source | — |
| Other Nonoperating Income (Expense)USD | -2,801,000Source | -6,906,000Source | 5,056,000Source | -5,522,000Source |
| Proceeds from Stock Options ExercisedUSD | 3,972,000Source | — | — | — |
| Provision for Loan, Lease, and Other LossesUSD | — | — | 822,000Source | — |
| Unrealized Gain (Loss) on InvestmentsUSD | 1,506,000Source | -899,000Source | 1,308,000Source | -11,406,000Source |
income statement · annual statements
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|
| Total RevenueUSD | 176,177,000Source | 228,385,000Source | 233,255,000Source | 237,277,000Source |
| Cost of Goods and Services Sold | — | — | — | — |
| Selling, General and Administrative ExpenseUSD | 102,819,000Source | 148,978,000Source | 146,880,000Source | 120,055,000Source |
| Operating Income (Loss)USD | -36,806,000Source | -130,866,000Source | -115,157,000Source | -31,904,000Source |
| Other Nonoperating Income (Expense)USD | -2,801,000Source | -6,906,000Source | 5,056,000Source | -5,522,000Source |
| Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling InterestUSD | -32,170,000Source | -113,480,000Source | -99,348,000Source | -35,094,000Source |
| Income Tax Expense (Benefit)USD | 1,799,000Source | 1,276,000Source | 239,000Source | 2,239,000Source |
| Net Income (Loss) Attributable to ParentUSD | 78,301,000Source | -114,756,000Source | -99,587,000Source | -37,333,000Source |
| Earnings Per Share, BasicUSD per share | 1.4Source | -2.49Source | -2.21Source | -0.93Source |
| Earnings Per Share, DilutedUSD per share | 1.4Source | -2.49Source | -2.21Source | -0.93Source |
| Weighted Average Number of Shares Outstanding, Basicshares | 50,071,665Source | 49,349,624Source | 48,737,377Source | 48,987,295Source |
| Weighted Average Number of Shares Outstanding, Dilutedshares | 50,071,665Source | 49,349,624Source | 48,737,377Source | 48,987,295Source |
| Interest Expense (non-operating)USD | 2,361,000Source | 4,108,000Source | — | — |
| Additional Financial Items | ||||
| Amortization of Intangible AssetsUSD | 12,700,000Source | 17,000,000Source | 16,300,000Source | 15,100,000Source |
| Current Income Tax Expense (Benefit)USD | 1,549,000Source | 1,722,000Source | 2,336,000Source | 2,704,000Source |
| Equity Securities, FV-NI, Realized Gain (Loss)USD | -203,000Source | -3,370,000Source | -3,764,000Source | -11,406,000Source |
| Foreign Currency Transaction Gain (Loss), before TaxUSD | 12,900,000Source | -4,300,000Source | -1,300,000Source | -9,800,000Source |
| Goodwill, Impairment LossUSD | 0Source | 54,563,000Source | 49,569,000Source | — |
| Gross ProfitUSD | 83,054,000Source | 99,631,000Source | 99,332,000Source | 103,873,000Source |
| Income (Loss) from Continuing Operations, Net of Tax, Attributable to ParentUSD | -33,969,000Source | — | — | — |
| Income (Loss) from Continuing Operations, Per Basic ShareUSD per share | -0.84Source | — | — | — |
| Income (Loss) from Continuing Operations, Per Diluted ShareUSD per share | -0.84Source | — | — | — |
| Income (Loss) from Discontinued Operations, Net of Tax, Attributable to ParentUSD | 112,270,000Source | — | — | — |
| Interest ExpenseUSD | — | — | 5,503,000Source | 6,142,000Source |
| Interest Expense, DebtUSD | — | — | 5,906,000Source | 6,033,000Source |
| Investment Income, NetUSD | 9,798,000Source | 9,895,000Source | 10,577,000Source | 8,474,000Source |
| Net Income (Loss) Available to Common Stockholders, BasicUSD | 70,301,000Source | -122,756,000Source | -107,587,000Source | -45,333,000Source |
| Nonoperating Income (Expense)USD | 4,636,000Source | 17,386,000Source | 15,809,000Source | -3,190,000Source |
| Operating ExpensesUSD | 119,860,000Source | 230,497,000Source | 214,489,000Source | 135,777,000Source |
| Operating Lease, ExpenseUSD | 6,596,000Source | 5,770,000Source | 5,103,000Source | — |
| Research and Development ExpenseUSD | 17,041,000Source | 17,710,000Source | 18,040,000Source | 15,722,000Source |
Filing attachments
tm2622464d1_ex99-1.htm · 8-K · 2026-08-06
EX-99.1 2 tm2622464d1_ex99-1.htm EXHIBIT 99.1 Exhibit 99.1 Cryoport Reports Second Quarter 2026 Financial Results Second quarter revenue grew 8% year-over-year to $49.0 million Life Sciences Services revenue increased 15% year-over-year ──────────────────────────────────────── BioStorage/BioServices revenue grew 25% year-over-year Supporting 779 global clinical trials and 22 commercially approved cell and gene therapies (CGT) as of June 30, 2026 ───────────────────────…
Read attachment ↗tm2613494d1_ex99-1.htm · 8-K · 2026-05-04
EX-99.1 2 tm2613494d1_ex99-1.htm EXHIBIT 99.1 Exhibit 99.1 Cryoport Reports First Quarter 2026 Financial Results First quarter revenue grew 16% year-over-year to $47.8 million Commercial cell and gene therapy (CGT) revenue grew 26% year-over-year to $9.1 million, reflecting continued expansion in approved CGT programs Life Sciences Services revenue increased 18% year-over-year, led by 21% growth in BioStorage/BioServices ────────────────────────────────────────────────────…
Read attachment ↗tm267876d1_ex99-1.htm · 8-K · 2026-03-03
EX-99.1 2 tm267876d1_ex99-1.htm EXHIBIT 99.1 Exhibit 99.1 Cryoport Reports Fourth Quarter and Full-Year 2025 Financial Results FY 2025 revenue increased to $176.2 million, exceeding the high end of previous guidance Life Sciences Services revenue grew 18% year-over-year in FY 2025, including a 22% rise in BioStorage/BioServices revenue Commercial cell and gene therapy revenue increased 29% year-over-year to $33.4 million in FY 2025 Supported a record 760 global clinica…
Read attachment ↗tm2530148d1_ex99-1.htm · 8-K · 2025-11-04
EX-99.1 2 tm2530148d1_ex99-1.htm EXHIBIT 99.1 Exhibit 99.1 Cryoport Reports Third Quarter 2025 Financial Results Third quarter revenue increased 15% year-over-year to $44.2 million Commercial Cell & Gene Therapy revenue increased 36% year-over-year to $8.3 million Life Sciences Services revenue grew 16% year-over-year, including a 21% rise in BioStorage/BioServices revenue Life Sciences Products revenue grew 15% year-over-year Company updates full year 2025 revenu…
Read attachment ↗tm2522626d1_ex99-1.htm · 8-K · 2025-08-06
EX-99.1 2 tm2522626d1_ex99-1.htm EXHIBIT 99.1 Exhibit 99.1 Cryoport Reports Second Quarter 2025 Financial Results Second quarter revenue increased 14% year-over-year to $45.5 million Commercial Cell & Gene Therapy revenue increased 33% year-over-year to $8.7 million Life Sciences Services revenue rose 21% year-over-year, including a 28% increase in BioStorage/BioServices revenue ─────────────────────────────────────────────────────────────────────────────────────────────── …
Read attachment ↗cyrx-20250611xex99d1.htm · 8-K · 2025-06-13
EX-99.1 2 cyrx-20250611xex99d1.htm EX-99.1 Exhibit 99.1 Cryoport Completes CRYOPDP Divestiture and Commences Strategic Partnership with DHL Group NASHVILLE, Tennessee, June 12, 2025 - Cryoport, Inc. (Nasdaq: CYRX) (“Cryoport” or the “Company”), a leader in temperature-controlled supply chain solutions for the Life Sciences, with a focus on regenerative medicine, today announced the completion of the previously disclosed divestiture of its specialty courier business, CRYOPDP, to DHL Group …
Read attachment ↗